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Abstract: 
Mycobacteria tuberculosis (Mtb) is a major cause of human morbidity and mortality.  
Transmission occurs through inhalation of aerosolized Mtb and the initial infection is believed to 
occur primarily in the alveolar macrophage, although Mtb can infect other cells residing in the 
lung including dendritic cells, pneumocytes and M cells. Several molecules derived from Mtb are 
involved in the attachment of the organism to host receptors (opsonic and non-opsonic), which 
have been reasonably well elucidated. However, a complete understanding of how Mtb attaches 
to the host and the relative importance of each mechanism on the outcome of infection remains 
elusive. 
We hypothesize that protection from infection is possible by blocking the critical initial surface 
interactions of the organism with the host cell using specific monoclonal antibodies (mAbs). To 
develop effective mAbs, the outermost layers of Mtb, the capsule and outer membrane, were 
isolated and characterized by protein gel and LC/MS/MS. Approximately 1000 different proteins 
were identified in the isolations, of which ~25% were unique to one of the two fractions. The 
capsule or outer membrane preparations were used as antigens to immunize CD1 mice for up 
to 12 weeks to generate antibodies via traditional hybridoma generation. Antibodies were 
screened, selected and characterized by their ability to bind whole cell Mtb by ELISA, 
demonstration of unique heavy chain variable region sequence and binding specificity by 
Western Blot. Of approximately 1500 screened hybridomas, 30 lead mAbs have been isolated 
with specificity to various targets. Preliminary results suggest several of the lead mAb 
candidates are able to prevent Mtb-induced macrophage cell death in vitro. Future studies will 
attempt to confirm efficacy in vivo after aerosolized infection in mice with mAb-coated Mtb or 
parenteral administration of mAb(s). Targets of functional mAbs will be determined and these 
antigens could serve as viable candidates for vaccine development.     
 
